Question · asked by 1 review
Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy): Health‐related quality of life3
- Population
- Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
- Intervention
- Bevacizumab + IFN
- Comparison
- IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy)
- Outcome
- Health‐related quality of life3
The review found no eligible studies for this question.
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Bevacizumab + IFN vs IFN (+ placebo) (targeted agent + classic immunotherapy versus classic immunotherapy) Health‐related quality of life3 · Treatment‐naïve metastatic renal cell carcinoma (clear cell type) The review found no eligible studies for this question. Targeted therapy for metastatic renal cell carcinoma (2020) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Targeted therapy for metastatic renal cell carcinoma 2020 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.